Condor Software Raises $24 Million Series A Funding to Build the First Financial Intelligence Platform for Life Sciences

Condor’s AI-powered platform automatically unifies clinical, operational, and financial data to empower life sciences companies to see, predict, and control the cost of bringing life-changing therapies to patients

Condor Software, the Financial Intelligence Platform for life sciences, announced it has closed a $24 million Series A funding round led by global software investor Insight Partners, with participation from Felicis, 645 Ventures, Pamir Ventures, SNR Ventures, Prebys Ventures, and Bramalea Partners. Condor has raised a total of $36 million in funding.

Pharmaceutical companies spend an estimated $300 billion annually on R&D. While AI is rapidly reshaping how drugs are discovered and developed, the financial infrastructure that determines which programs get funded still runs on spreadsheets that require manual reconciliation across disconnected CRO portals, ERP systems, and accounting tools. As a result, many promising trials are paused or cancelled because accounting, FP&A, and clinical operations teams lack real-time clarity on trial spend, budget performance, asset value, and whether additional investment is justified.

Read More on Fintech : Global Fintech Interview with Baran Ozkan, co-founder & CEO of Flagright

Condor’s Founder and CEO Jennifer Kyle built the accounting workflows that the pharmaceutical industry uses to manage clinical trial finances. She founded Condor, and built the company’s AI-powered Financial Intelligence Platform, to automatically consolidate clinical, operational, and financial data and enable life sciences teams to move faster, save money, and operate with confidence. Condor’s platform is built on proprietary clinical and financial ontologies that map the relationships between trial protocols, site-level activity, vendor contracts, and accounting rules. The platform’s knowledge architecture was developed over years with Big 4 accounting firms and embedded in audit-grade workflows. The platform features three core modules:

• Connect integrates clinical and financial data across the enterprise ecosystem into a single source of truth.
• Compass forecasts costs, models scenarios, and surfaces risk as programs evolve.
• Copilot automates accruals, reconciliations, and monthly close tasks.

Condor manages over $19 billion in R&D spend and is trusted by accounting, FP&A, and clinical operations teams at emerging biotechs and leading biopharma organizations, including Acadia Pharmaceuticals, Alumis Therapeutics, BridgeBio Pharma, and Madrigal Pharmaceuticals. The company’s customers report over 90 percent forecast accuracy, 70 percent faster month-end close, and 30 percent average budget savings.

Condor will leverage its Series A funding to accelerate the expansion of its platform, bolster its enterprise capabilities for industry-leading pharmaceutical companies, and scale its engineering, product, design, sales, and customer success teams, building upon a team that includes leaders with experience at Medidata, BenchSci, Oracle, Benchling, Salesforce Life Sciences, and EY.